Oxelumab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
No edit summary |
||
| Line 57: | Line 57: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 13:04, 18 March 2025
| Oxelumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1186098-83-8 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Oxelumab is a human monoclonal antibody designed for the treatment of asthma.<ref>
Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab(link). {{{website}}}. American Medical Association.
</ref>
Oxelumab was developed by Genentech and co-developed by Roche.
References[edit]
<references/>
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
